SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society. Cancer Facts and Figures, 2005. Atlanta: American Cancer Society; 2005.
  • 2
    Travis LB, Curtis RE, Glimelius B, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst. 1993; 85: 19321937.
  • 3
    Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003; 21: 897906.
  • 4
    Pedersen-Bjergaard J, Ersboll J, Hansen VL, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med. 1988; 318: 10281032.
  • 5
    Pedersen-Bjergaard J, Ersboll J, Sorensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med. 1985; 103: 195200.
  • 6
    Pedersen-Bjergaard J, Jonsson V, Pedersen M, Hou-Jensen K. Leiomyosarcoma of the urinary bladder after cyclophosphamide. J Clin Oncol. 1995; 13: 532533.
  • 7
    Travis LB, Curtis RE, Boice JD Jr., Fraumeni JF Jr. Bladder cancer after chemotherapy for non-Hodgkin's lymphoma. N Engl J Med. 1989; 321: 544545.
  • 8
    Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994; 12: 25272534.
  • 9
    Greene MH, Young RC, Merrill JM, DeVita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res. 1983; 43: 18911898.
  • 10
    Lenz G, Dreyling M, Schiegnitz E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol. 2004; 22: 49264933.
  • 11
    Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994; 12: 25352542.
  • 12
    Boice JD. Cancer following medical irradiation. Cancer. 1981; 47(5 Suppl ): 10811090.
  • 13
    Boice JD Jr. Radiation and breast carcinogenesis. Med Pediatr Oncol. 2001; 36: 508513.
  • 14
    National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat, ver 5.3.1. [computer program]. Bethesda: National Cancer Institute.
  • 15
    Breslow NH, Lubin JH, Marek P, Langholz B. Multiplicative models and cohort analysis. J Am Stat Assoc. 1983; 78: 112.
  • 16
    Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004; 103: 12221228.
  • 17
    Oddou S, Vey N, Viens P, et al. Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution. Leuk Lymphoma. 1998; 31(1-2): 187194.
  • 18
    Moertel CG, Hagedorn AB. Leukemia or lymphoma and coexistent primary malignant lesions: a review of the literature and a study of 120 cases. Blood. 1957; 12: 788803.
  • 19
    Berg JW. The incidence of multiple primary cancers. I. Development of further cancers in patients with lymphomas, leukemias, and myeloma. J Natl Cancer Inst. 1967; 38: 741752.
  • 20
    Zarrabi MH. Association of non-Hodgkin's lymphoma (NHL) and second neoplasms. Semin Oncol. 1980; 7: 340351.
  • 21
    MacDougall BK, Weinerman BH, Kemel S. Second malignancies in non-Hodgkin's lymphoma. Cancer. 1981; 48: 12991301.
  • 22
    Storm HH, Prener A. Second cancer following lymphatic and hematopoietic cancers in Denmark, 1943-80. Natl Cancer Inst Monogr. 1985; 68: 389409.
  • 23
    RiesLAG, EisnerM, KosaryCL, et al., editors. SEER Cancer Statistics Review, 1975-2002. Bethesda: National Cancer Institute; 2005.
  • 24
    Gandhok N, Sartor O. Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen. Urology. 2004; 64: 807809.
  • 25
    Latz D, Nassar N, Frank R. Trofosfamide in the palliative treatment of cancer: a review of the literature. Onkologie. 2004; 27: 572576.
  • 26
    Amling CL. The association between obesity and the progression of prostate and renal cell carcinoma. Urol Oncol. 2004; 22: 478484.
  • 27
    Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomarkers Prev. 2005; 14: 275279.
  • 28
    Greenwald P. Lifestyle and medical approaches to cancer prevention. Recent Results Cancer Res. 2005; 166: 115.
  • 29
    Blanchard CM, Denniston MM, Baker F, et al. Do adults change their lifestyle behaviors after a cancer diagnosis? Am J Health Behav. 2003; 27: 246256.
  • 30
    Bauld C, Toumbourou JW, Anderson V, Coffey C, Olsson CA. Health-risk behaviours among adolescent survivors of childhood cancer. Pediatr Blood Cancer. 2005; 45: 706715.
  • 31
    van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003; 95: 971980.
  • 32
    Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003; 290: 465475.
  • 33
    Pothuri B, Ramondetta L, Martino M, et al. Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gynecol. 2003; 101(5 Pt 1): 941945.
  • 34
    West JG, Qureshi A, West JE, et al. Risk of angiosarcoma following breast conservation: a clinical alert. Breast J. 2005; 11: 115123.
  • 35
    Rubino C, Shamsaldin A, Le MG, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat. 2005; 89: 277288.
  • 36
    National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. SEER data quality. Available at URL: http://seer.cancer.gov/about/quality.html Accessed May 6, 2005.
  • 37
    National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program (available at URL: www.seer.cancer.gov). SEER*Stat data base: incidence-SEER 13 registries, public use, 1973-2002 varying (based on the November 2004 submission; released April 2005). Bethesda: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2005.